SEARCH

SEARCH BY CITATION

References

  • 1
    Ogilvie K, Reynolds HA, Richardson RC, et al. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 1989;195:15801583.
  • 2
    Berg J, Weinstein MJ, Springfield DS, et al. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:15551560.
  • 3
    Ogilvie GK, Powers BE, Mallinckrodt CH, et al. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med 1996;10:379384.
  • 4
    Ogilvie GK, Richardson RC, Curtis CR, et al. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 1989;195:15851587.
  • 5
    Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting. Drugs 2009;69:515533.
  • 6
    Benchaoui HA, Cox SR, Schneider RP, et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Therap 2007;30:336344.
  • 7
    Navari RM. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: Summary of clinical trials. Cancer Invest 2004;24:569576.
  • 8
    Vail DM, Rodabaugh HS, Conder GA, et al. Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin induced emesis in dogs presented as veterinary patients. Vet Comp Oncol 2007;5:3846.
  • 9
    De la Puente-Redondo VA, Tilt N, Rowan TG, et al. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am J Vet Res 2007;68:4856.
  • 10
    Kris MG, Hesketh PJ, Somerfield MR, et al. American society of clinical oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006;24:29322957.
  • 11
    Food and Drug Administration. Freedom of information summary: Cerenia (maropitant citrate) injectable solution for the prevention and treatment of acute vomiting in dogs. NADA #141263. 2007.
  • 12
    Veterinary Co-operative Oncology Group Common Terminology Criteria for Adverse Events (VCOG-CTCAE). A consensus document from the VCOG. Vet Comp Oncol 2004;2:194213.
  • 13
    Koon HW, Pothoulakis C. Immunomodulatory properties of substance P: The gastrointestinal tract as a model. Ann NY Acad Sci 2006;1088:2340.
  • 14
    Holzer P, Holzer-Petsche U. Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol Ther 1997;73:173217.
  • 15
    Holzer P, Holzer-Petsche U. Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. Pharmacol Ther 1997;73:219263.
  • 16
    Renzi D, Pelegrini B, Tenelli F, et al. Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine. Am J Pathol 2000;157:15111522.
  • 17
    Pothoulakis C, Castagliuolo I, Leeman SE, et al. Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats. Am J Physiol 1998;275:6875.
  • 18
    O'Connor TM, O'Connell J, O'Brien DI, et al. The role of substance P in inflammatory disease. J Cell Physiol 2004;201:167180.
  • 19
    Pernow B. Substance P. Pharmacol Rev 1983;35:85141.
  • 20
    Lordal M, Hallgren A, Nylander O, et al. Tachykinins increase vascular permeability in the gastrointestinal tract of the rat. Acta Physiol Scand 1996;156:489494.
  • 21
    Robinson P, Okhuysen PC, Chappell CL, et al. Substance P expression correlates with severity of diarrhea in Cryptosporidiosis. J Infect Dis 2003;188:290296.
  • 22
    Mazumdar S, Das KM. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol 1992;87:176181.
  • 23
    Alvaro G, DiFabio R. Neurokinin 1 receptor antagonists—current prospects. Curr Opin Drug Discov Devel 2007;10:613621.
  • 24
    Sonea IM, Palmer MV, Akili D, et al. Treatment with neurokinin-1 receptor antagonist reduces severity of inflammatory bowel disease induced by Cryptosporidium parvum. Clin Diagn Lab Immunol 2002;9:333340.
  • 25
    Robinson P, Martin P, Garza A, et al. Substance P receptor antagonism for treatment of cryptosporidiosis in immunosuppressed mice. J Parasitol 2008;94:11501154.
  • 26
    Moriarty D, Goldhill J, Selve N, et al. Human colonic anti-secretory activity of the potent NK1 antagonist, SR140333: Assessment of potential anti-diarrhoeal activity in food allergy and inflammatory bowel disease. Br J Pharmacol 2001;133:13461354.
  • 27
    Schnell FM. Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control. Oncologist 2003;8:187198.
  • 28
    ASHP Commission on Therapeutics. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729764.